High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: A study using formalin-fixed, paraffin-embedded archival tissues

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1590-1595

  Chaux, Alcides ^a   Cohen, Julie S ^b   Schultz, Luciana ^a   Albadine, Roula ^a   Jadallah, Sana ^a   Murphy, Kathleen M ^c   Sharma, Rajni ^a   Schoenberg, Mark P ^a   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c ProPath   (United States)

Author keywords

EGFR expression; EGFR mutation; Exon 19 deletion; Exon 21 L858R substitution; Urothelial carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; DNA EXTRACTION; EXON; EXON 19; EXON 21; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

AGED; BIOLOGICAL SPECIMEN BANKS; CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE FIXATION; URINARY BLADDER NEOPLASMS;

EID: 84866482706     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.11.016     Document Type: Article

References (22)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675 (Pubitemid 32120143)
3. S. Madersbacher, W. Hochreiter, and F. Burkhard Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696 (Pubitemid 46621904)
4. I. Zachos, P.A. Konstantinopoulos, and V. Tzortzis Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise Expert Opin Investig Drugs 19 2010 875 887
5. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608 (Pubitemid 46224062)
6. J.R. Grandis, and J.C. Sok Signaling through the epidermal growth factor receptor during the development of malignancy Pharmacol Ther 102 2004 37 46 (Pubitemid 38429984)
7. M. Ono, and M. Kuwano Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 2006 7242 7251 (Pubitemid 46095395)
8. L. Chintala, and R. Kurzrock Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review Mol Oncol 4 2010 306 308
9. F. Leone, G. Cavalloni, and Y. Pignochino Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma Clin Cancer Res 12 2006 1680 1685
10. G.J. Villares, M. Zigler, and K. Blehm Targeting EGFR in bladder cancer World J Urol 25 2007 573 579
11. K.N. Blehm, P.E. Spiess, and J.E. Bondaruk Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy Clin Cancer Res 12 2006 4671 4677 (Pubitemid 44297820)
12. W. Kassouf, P.C. Black, and T. Tuziak Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer J Urol 179 2008 353 358 (Pubitemid 350216717)
13. N.H. Chow, S.H. Chan, T.S. Tzai, C.L. Ho, and H.S. Liu Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder Clin Cancer Res 7 2001 1957 1962
14. A.R. Li, D. Chitale, and G.J. Riely EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression J Mol Diagn 10 2008 242 248 (Pubitemid 351692167)
15. Z. Popov, S. Gil-Diez-De-Medina, and V. Ravery Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications Urol Oncol 22 2004 93 101 (Pubitemid 38479801)
16. S. Leibl, R. Zigeuner, G. Hutterer, T. Chromecki, P. Rehak, and C. Langner EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology APMIS 116 2008 27 32 (Pubitemid 351191103)
17. J.L. Dominguez-Escrig, J.D. Kelly, D.E. Neal, S.M. King, and B.R. Davies Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer Clin Cancer Res 10 2004 4874 4884 (Pubitemid 38955542)
18. H.W. Lo Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications Discov Med 10 2010 44 51
19. F. Ciardiello, and G. Tortora Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs Eur J Cancer 39 2003 1348 1354 (Pubitemid 36773776)
20. S. Jarvela, H. Helin, and J. Haapasalo Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival Neuropathol Appl Neurobiol 32 2006 441 450 (Pubitemid 44015585)
21. A. Franovic, L. Gunaratnam, K. Smith, I. Robert, D. Patten, and S. Lee Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer Proc Natl Acad Sci U S A 104 2007 13092 13097 (Pubitemid 351737598)
22. M.D. Marmor, and Y. Yarden Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases Oncogene 23 2004 2057 2070 (Pubitemid 38496735)